End-of-day quote
Pakistan S.E.
03:30:00 03/05/2024 am IST
|
5-day change
|
1st Jan Change
|
100.1
PKR
|
+2.07%
|
|
-0.29%
|
+20.63%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
35,885
|
51,136
|
61,092
|
43,474
|
27,952
|
26,430
|
Enterprise Value (EV)
1 |
32,452
|
48,498
|
55,079
|
35,045
|
23,543
|
23,544
|
P/E ratio
|
11
x
|
16.8
x
|
18.1
x
|
8.12
x
|
11.3
x
|
49.5
x
|
Yield
|
6.21%
|
3.74%
|
3.39%
|
5.13%
|
-
|
-
|
Capitalization / Revenue
|
1.06
x
|
1.4
x
|
1.74
x
|
1.19
x
|
0.67
x
|
0.53
x
|
EV / Revenue
|
0.95
x
|
1.33
x
|
1.57
x
|
0.96
x
|
0.56
x
|
0.47
x
|
EV / EBITDA
|
5.87
x
|
8.65
x
|
9.73
x
|
4.59
x
|
4.01
x
|
8.17
x
|
EV / FCF
|
15.6
x
|
31.1
x
|
11.9
x
|
9.89
x
|
-15.6
x
|
-20.9
x
|
FCF Yield
|
6.42%
|
3.22%
|
8.37%
|
10.1%
|
-6.41%
|
-4.78%
|
Price to Book
|
2.33
x
|
3.17
x
|
3.5
x
|
2.07
x
|
1.33
x
|
1.22
x
|
Nbr of stocks (in thousands)
|
3,18,467
|
3,18,467
|
3,18,467
|
3,18,467
|
3,18,467
|
3,18,467
|
Reference price
2 |
112.7
|
160.6
|
191.8
|
136.5
|
87.77
|
82.99
|
Announcement Date
|
03/04/19
|
29/04/20
|
06/04/21
|
04/04/22
|
28/03/23
|
01/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
34,007
|
36,582
|
35,090
|
36,661
|
41,842
|
49,661
|
EBITDA
1 |
5,526
|
5,606
|
5,658
|
7,634
|
5,874
|
2,881
|
EBIT
1 |
4,863
|
4,811
|
4,909
|
6,873
|
5,068
|
1,965
|
Operating Margin
|
14.3%
|
13.15%
|
13.99%
|
18.75%
|
12.11%
|
3.96%
|
Earnings before Tax (EBT)
1 |
4,692
|
4,600
|
4,903
|
7,424
|
5,106
|
2,177
|
Net income
1 |
3,258
|
3,041
|
3,375
|
5,354
|
2,463
|
534
|
Net margin
|
9.58%
|
8.31%
|
9.62%
|
14.61%
|
5.89%
|
1.08%
|
EPS
2 |
10.23
|
9.549
|
10.60
|
16.81
|
7.734
|
1.677
|
Free Cash Flow
1 |
2,084
|
1,559
|
4,609
|
3,545
|
-1,509
|
-1,126
|
FCF margin
|
6.13%
|
4.26%
|
13.14%
|
9.67%
|
-3.61%
|
-2.27%
|
FCF Conversion (EBITDA)
|
37.71%
|
27.81%
|
81.47%
|
46.44%
|
-
|
-
|
FCF Conversion (Net income)
|
63.95%
|
51.27%
|
136.57%
|
66.21%
|
-
|
-
|
Dividend per Share
2 |
7.000
|
6.000
|
6.500
|
7.000
|
-
|
-
|
Announcement Date
|
03/04/19
|
29/04/20
|
06/04/21
|
04/04/22
|
28/03/23
|
01/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
3,433
|
2,638
|
6,013
|
8,429
|
4,408
|
2,886
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
2,084
|
1,559
|
4,609
|
3,545
|
-1,509
|
-1,126
|
ROE (net income / shareholders' equity)
|
22.4%
|
19.3%
|
20.1%
|
27.8%
|
11.7%
|
2.5%
|
ROA (Net income/ Total Assets)
|
13.8%
|
13.2%
|
12.4%
|
15.2%
|
9.6%
|
3.33%
|
Assets
1 |
23,608
|
22,958
|
27,117
|
35,229
|
25,657
|
16,016
|
Book Value Per Share
2 |
48.40
|
50.70
|
54.90
|
65.90
|
66.10
|
68.10
|
Cash Flow per Share
2 |
10.00
|
7.370
|
17.60
|
22.20
|
14.90
|
11.30
|
Capex
1 |
855
|
1,343
|
1,316
|
1,304
|
1,533
|
1,649
|
Capex / Sales
|
2.51%
|
3.67%
|
3.75%
|
3.56%
|
3.66%
|
3.32%
|
Announcement Date
|
03/04/19
|
29/04/20
|
06/04/21
|
04/04/22
|
28/03/23
|
01/04/24
|
|
1st Jan change
|
Capi.
|
---|
| +20.63% | 115M | | +26.08% | 662B | | +21.85% | 546B | | -4.77% | 359B | | +16.97% | 323B | | +5.69% | 290B | | +13.68% | 234B | | +3.65% | 198B | | -11.12% | 194B | | -3.40% | 157B |
Other Pharmaceuticals
|